Chronic Lymphocytic Leukemia News and Research

RSS
Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions.
How and when do de novo SARS-CoV-2 spike mutations emerge?

How and when do de novo SARS-CoV-2 spike mutations emerge?

Novel app can help doctors make better decisions for patients with leukemia.

Novel app can help doctors make better decisions for patients with leukemia.

Triple BNT162b2 vaccination found to establish long-term T lymphocyte immunity among MDS and CLL patients

Triple BNT162b2 vaccination found to establish long-term T lymphocyte immunity among MDS and CLL patients

Third dose of messenger RNA vaccines found to increase serological immunity in hematological malignancy patients

Third dose of messenger RNA vaccines found to increase serological immunity in hematological malignancy patients

Immunocompromised hosts with Delta/Omicron co-infections

Immunocompromised hosts with Delta/Omicron co-infections

Molecular signature of highly stereotyped clonotypic anti-PF4 antibodies indicates shared pathways of antibody production in VITT patients

Molecular signature of highly stereotyped clonotypic anti-PF4 antibodies indicates shared pathways of antibody production in VITT patients

Vaccine-induced antibody response to SARS-CoV-2 Omicron variant in patients with B cell malignancies with and without active B cell-targeted therapy

Vaccine-induced antibody response to SARS-CoV-2 Omicron variant in patients with B cell malignancies with and without active B cell-targeted therapy

Most cancer patients develop antibodies after receiving COVID-19 vaccine, study shows

Most cancer patients develop antibodies after receiving COVID-19 vaccine, study shows

Impact of exogenous antibody therapy by convalescent plasma against SARS-CoV-2

Impact of exogenous antibody therapy by convalescent plasma against SARS-CoV-2

Combination treatment can provide long remissions for young patients with chronic lymphocytic leukemia

Combination treatment can provide long remissions for young patients with chronic lymphocytic leukemia

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

CIRM awards $4.1 million to advance CAR T-cell therapy from the lab to clinic

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Those undergoing treatment for hematological malignancies show reduced immune response to COVID-19 vaccines

Those undergoing treatment for hematological malignancies show reduced immune response to COVID-19 vaccines

mRNA BNT162b2 vaccine safe in immunocompromised patients

mRNA BNT162b2 vaccine safe in immunocompromised patients

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

Implications of persistent SARS-CoV-2 infection in patients with lymphoid malignancies

Study identifies mechanism of resistance and presents a much-needed target for advanced leukemias

Study identifies mechanism of resistance and presents a much-needed target for advanced leukemias

Researchers develop a new way to tag tumor cells to understand cancer treatment resistance

Researchers develop a new way to tag tumor cells to understand cancer treatment resistance

Combination therapy improves outcomes for relapsed chronic lymphocytic leukemia

Combination therapy improves outcomes for relapsed chronic lymphocytic leukemia